Immuron Extends ATM Funding Facility to Enhance Financial Flexibility

The latest announcement is out from Immuron Limited ( (AU:IMC) ).

Immuron Limited has filed an ATM supplementary prospectus with the U.S. Securities and Exchange Commission to extend its At-the-market (ATM) funding facility with H.C. Wainwright & Co., LLC. This strategic move allows Immuron to raise approximately US$2,847,954, providing the company with financial flexibility and an efficient mechanism to raise additional equity capital in response to operational needs and market opportunities.

More about Immuron Limited

Immuron Limited is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. One of its key products, Travelan®, is designed to reduce the risk of travelers’ diarrhea and is available as a listed medicine in Australia, a licensed natural health product in Canada, and a dietary supplement in the U.S.

YTD Price Performance: 16.46%

Average Trading Volume: 244,435

Technical Sentiment Signal: Buy

Current Market Cap: A$24.68M

See more data about IMC stock on TipRanks’ Stock Analysis page.